Scott Requadt - 01 Feb 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Role: Chief Executive Officer, Director
Signature: /s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol: TRML
Transactions as of: 01 Feb 2022
Net transactions value: +$19,110
Form type: 4
Filing time: 02 Feb 2022, 17:01:43 UTC
Next filing: 01 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TALS	Common Stock	Award	$19,110	+1,470	+0.33%	$13.00	451,236	31 Dec 2021	Direct	F1
holding	TALS	Common Stock						449,766	01 Feb 2022	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TALS	Stock Option (Right to Buy)	Award	$0	+500,000		$0.000000	500,000	01 Feb 2022	Common Stock	500,000	$9.10	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired by the reporting individual under the issuer's 2021 Employee Stock Purchase Plan ("ESPP") in a transaction exempt under Rule 16b-3(c).
F2	These shares are held by Requadt Family Limited Partnership. The reporting person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.
F3	The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter.